McPherson's owns a portfolio of everyday Australian consumer brands — Manicare, Swisspers, Lady Jayne, Dr LeWinn's, and Fusion Health — sold primarily through Chemist Warehouse and pharmacy chains. At A$0.19 versus a fair value of A$0.52, the stock is undervalued by 174%. The key driver is simple: the market is pricing permanent distress, but the company's own segment data already shows the cost restructuring is working.

McPherson's is best suited to patient value investors comfortable holding a micro-cap through a binary catalyst. The 174% gap to fair value is large, net cash of A$12.6m covers 46% of the entire market capitalisation, and even a partial recovery scenario delivers meaningful returns. The risk is concentration — one customer, one critical brand recovery, one unresolved regulatory matter — so position sizing matters as much as the thesis itself.

McPherson's is a consumer brand owner that develops and markets personal care, beauty, and health products through pharmacy and grocery channels across Australia and New Zealand. It earns revenue by selling branded goods — primarily Manicare hair and beauty tools, Swisspers cotton products, Lady Jayne accessories, Dr LeWinn's skincare, and Fusion Health supplements — to retailers who sell them to consumers.

The past two years have been defined by deliberate disruption. Management exited owned warehousing, transferred logistics to a third-party operator, restructured the brand portfolio by winding down lower-margin lines, and absorbed short-term revenue pain in exchange for a structurally lower cost base. First-half FY26 results confirmed the cost savings are materialising: the ANZ segment delivered a 9.1% EBITDA margin on reduced revenue, compared to a historical peak of 5.3% for the full business. The counterpoint is that Dr LeWinn's revenue fell 21.6% in the half, reflecting genuine brand weakness that the restructuring cannot fix.

The investment case rests on a straightforward gap between what the market prices and what the segment data shows. The market implies EBITDA will stay depressed permanently. The ANZ segment data implies the opposite — that a leaner cost structure is already generating economics the old model never achieved. Sixty-one per cent of fair value derives from cash flows in the next five years, underpinned by a three-year tax holiday from $149m in accumulated losses.

At A$0.19 versus a fair value of A$0.52, the stock is undervalued by 174%.

What happened?

First-half FY26 revenue of A$66.0m was weaker than the prior period, dragged lower by Dr LeWinn's supply disruptions and the intentional wind-down of lower-margin portfolio brands. The better news was underneath: the ANZ segment's 9.1% EBITDA margin confirmed that removing warehousing costs and restructuring headcount has structurally shifted the economics, not merely deferred costs. Manicare grew 6.7% and Swisspers 11.7% — the core brands are performing.

What's next?

The FY26 full-year result in August 2026 is the critical test. Second-half EBITDA needs to reach approximately A$6.0–6.5m to confirm the restructuring is delivering at scale, not just in a favourable half. Dr LeWinn's second-half revenue is the single most watched number — a return above A$10m would signal the packaging refresh and supply restoration are working. Below A$7m would shift the probabilities decisively toward the Bear scenario.

Beyond FY26, the portfolio brand exit completes by FY29, removing approximately A$7.5m in lower-margin revenue in FY26 alone. Once that drag is gone, the remaining portfolio — Manicare, Swisspers, Lady Jayne, Dr LeWinn's, and Fusion Health — grows at a modest but positive rate against a leaner cost base. Revenue effectively flatlines in FY26–27 before recovering. EBITDA, however, is forecast to expand from A$7.3m in FY25 to A$9.5m in FY27 as the structural cost savings flow through in full.

An ASIC regulatory matter from prior periods remains unresolved and unquantified. It represents the one risk that could disrupt an otherwise straightforward recovery trajectory.

What could go wrong?

The single biggest risk is customer concentration. One retailer — Chemist Warehouse — accounts for approximately 42% of McPherson's revenue. The relationship is anchored by a Promotional Brand Arrangement that gives McPherson's privileged shelf access, but that arrangement is subject to periodic renegotiation. If Chemist Warehouse were to renegotiate terms materially, reduce shelf space, or favour competing brands or its own private label, the revenue impact would be immediate and severe. A 20% reduction in Chemist Warehouse volumes alone would eliminate the entire EBITDA improvement forecast for FY27 and push fair value toward the Severe scenario of A$0.20 — close to where the stock already trades. Unlike the brand recovery risk, which unfolds gradually and gives investors time to respond, a customer relationship event could reprice the stock in a single announcement. It is the one scenario that makes the current market price look prescient rather than pessimistic.